We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current CCCC market cap is 301.84M. The company's latest EPS is USD -1.9314 and P/E is -2.27.
| Quarter End | Dec 2022 | Mar 2023 | Jun 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 2.85M | 3.76M | 6.42M | 3.26M | 3.04M |
| Operating Income | -38.29M | -36.23M | -73.8M | -37.43M | -32.22M |
| Net Income | -37.19M | -34.78M | -70.7M | -34.75M | -28.36M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 21.38M | 33.2M | 45.79M | 31.1M | 20.76M |
| Operating Income | -35.45M | -60.45M | -82.13M | -129.53M | -139.03M |
| Net Income | -42.57M | -66.34M | -83.89M | -128.18M | -132.49M |
| Quarter End | Dec 2022 | Mar 2023 | Jun 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 430.84M | 396.04M | 375.01M | 376.45M | 398.37M |
| Total Liabilities | 141.61M | 133.57M | 141.3M | 130.34M | 140.09M |
| Total Equity | 289.23M | 262.47M | 233.71M | 246.11M | 258.28M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 118.26M | 400.14M | 506.77M | 430.84M | 376.45M |
| Total Liabilities | 119.23M | 119.35M | 117.16M | 141.61M | 130.34M |
| Total Equity | -111.96M | 280.79M | 389.61M | 289.23M | 246.11M |
| Quarter End | Dec 2022 | Mar 2023 | Jun 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -105.94M | -33.13M | -52.12M | -106.84M | -18.12M |
| Investing | 58.42M | 53.53M | 68.68M | 158.35M | -53.4M |
| Financing | 1.15M | -684k | -1.43M | 45.49M | 34.58M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 55.61M | -67.25M | -86.97M | -105.94M | -106.84M |
| Investing | -1.62M | -190.51M | -189.34M | 58.42M | 158.35M |
| Financing | 244k | 348.93M | 171.4M | 1.15M | 45.49M |
| Market Cap | 301.84M |
| Price to Earnings Ratio | -2.27 |
| Price to Sales Ratio | 14.47 |
| Price to Cash Ratio | 2.37 |
| Price to Book Ratio | 1.22 |
| Dividend Yield | - |
| Shares Outstanding | 68.6M |
| Average Volume (1 week) | 1.21M |
| Average Volume (1 Month) | 1.17M |
| 52 Week Change | 17.02% |
| 52 Week High | 11.88 |
| 52 Week Low | 1.06 |
| Spread (Intraday) | 4.75 (53.67%) |
| Company Name | C4 Therapeutics Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.c4therapeutics.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
